SecBot SecBot
SECBOTREPLAY Home › Report › GSK

GSK · GSK announced that Japan's MHLW approved a prefilled syringe…

GSK plc · 6-K filed Sep 10, 2026 at 06:09 ET

At the news

NEUTRALIMPACT 3/10

6-K filed Sep 10, 2026 at 06:09 ET

GSK announced that Japan's MHLW approved a prefilled syringe presentation of Shingrix for shingles prevention. The ready-to-use format simplifies administration but does not change the indication or dosing, and the same presentation already launched in the US in February 2026 and is rolling out across Europe this year. No financial figures were disclosed, making this an incremental commercial convenience update rather than a material standalone catalyst.

  • Japan's MHLW approved a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine) for prevention of shingles.
  • The vaccine has been approved in Japan since 2018 for adults 50+ and since 2023 for adults 18+ at increased risk.
  • The prefilled syringe is ready-to-use, replacing the prior two-vial mix-before-use presentation.
  • Approval is based on technical comparability data; no change in indication or dosing.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access